AndreaBozzo/ceres-open-data-index huggingface dataset:
Medically Underserved Areas / Populations

<a href='https://files.hawaii.gov/dbedt/op/gis/data/mua_medically_underserved_areas.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>[Metadata</a>]  Medically Underserved Areas/Populations (MUA/P) for the State of Hawaii as of March 2025. Source:  US Health Resources and Services Administration (HRSA). Downloaded by the Hawaii State GIS Program from the Federal Health Resources and Services Administrations (HRSA) website, 3/10/25 (<a href='https://data.hrsa.gov/data/download' target='_blank' rel='nofollow ugc noopener noreferrer'>https://data.hrsa.gov/data/download</a>). These data describe geographic areas and populations with a lack of access to primary care health services. Medically Underserved Areas (MUAs) may be a whole county or a group of contiguous counties, a group of county or civil divisions or a group of urban census tracts in which residents have a shortage of personal health services. Medically Underserved Populations (MUPs) may include groups of persons who face economic, cultural or linguistic barriers to health care. HRSA's Bureau of Health Workforce develops shortage designation criteria and uses them to decide whether or not a geographic area or population group is a MUA or MUP.For more information about this layer and attribute values and meanings please see <a href='https://files.hawaii.gov/dbedt/op/gis/data/mua_medically_underserved_areas.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>https://files.hawaii.gov/dbedt/op/gis/data/mua_medically_underserved_areas.pdf</a> or contact the Hawaii Statewide GIS Program, Office of Planning and Sustainable Development, State of Hawaii; PO Box 2359, Honolulu, Hi. 96804; (808) 587-2846; email: <a href='mailto:gis@hawaii.gov' target='_blank' rel='nofollow ugc noopener noreferrer'>gis@hawaii.gov</a>; Website: <a href='https://planning.hawaii.gov/gis' target='_blank' rel='nofollow ugc noopener noreferrer'>https://planning.hawaii.gov/gis</a>.
Compound 525081: 1-(10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1,2-diol

Chemical compound data from PubChem database. IUPAC Name: 1-(10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1,2-diol. Molecular Formula: C21H36O2. Molecular Weight: 320.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD COVID-19 - Total Deaths in Congregate Facility Settings (Nursing Homes, Assisted Living, State and Local Facilities and Group Homes +10 Residents)

<b>Summary</b>
<b>This layer has been DEPRECATED</b> (last updated 12/1/2021). Was formerly a weekly update.

The Outbreak-Associated Cases in Congregate Living data dashboard on coronavirus.maryland.gov was redesigned on 11/17/21 to align with other outbreak reporting. Visit https://opendata.maryland.gov/dataset/MD-COVID-19-Congregate-Outbreak/ey5n-qn5s to view Outbreak-Associated Cases in Congregate Living data as reported after 11/17/21.

Confirmed COVID-19 deaths among Maryland residents who live and work in congregate living facilities in Maryland for the reporting period.

<b>Description</b>
The MD COVID-19 - Total Deaths in Congregate Facility Settings data layer is a total of deaths confirmed by a positive COVID-19 test result that have been reported to MDH in nursing homes, assisted living facilities, group homes of 10 or more and state and local facilities for the reporting period. Data are reported to MDH by local health departments, the Department of Public Safety and Correctional Services and the Department of Juvenile Services. To appear on the list, facilities report at least one confirmed case of COVID-19 over the prior 14 days. Facilities are removed from the list when health officials determine 14 days have passed with no new cases and no tests pending. The list provides a point-in-time picture of COVID-19 case activity among these facilities. Numbers reported for each facility listed reflect totals ever reported for deaths. Data are updated once weekly.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Compound 528328: Furfuryl 2-propenyl sulfide

Chemical compound data from PubChem database. IUPAC Name: 1-(prop-2-enylsulfanylmethyl)cyclopenta-1,3-diene. Molecular Formula: C9H12S. Molecular Weight: 152.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525241: N''-(3-methoxy-phenyl)-N,N,N',N'-tetramethyl-guanidine

Chemical compound data from PubChem database. IUPAC Name: 2-(3-methoxyphenyl)-1,1,3,3-tetramethylguanidine. Molecular Formula: C12H19N3O. Molecular Weight: 221.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400538-T1: [Translated] AIUMINIUM NITRIDE SUBSTRATE AND METHOD FOR PREPARING THIS SUBSTRATE FOR CONNECTION TO A COPPER FOIL

In an aluminum nitride (AlN) substrate (1), which has layer(s) (10) of AlN and an ancillary layer, on at least one surface, to which a copper foil (2) can be fixed by the direct copper bonding (DCB) process, the ancillary layer (4) comprises  NOTLESS  50 wt.% copper aluminate, CuAlO2, and contains an excess of copper-I oxide, Cu2O. An Independent claim is also included for the preparation of an AlN substrate for bonding with a Cu foil by a DCB process by applying a layer of Cu, Cu oxide or other compounds containing Cu to at least one surface and oxidation to form CuAl2O4, in which oxidation is followed by reduction to reduce the CuAl2O4 to CuAlO2 and the CuO to Cu2O.
Compound 528841: Glycerol, 2,3-dimethyl, 1-dodecanoate

Chemical compound data from PubChem database. IUPAC Name: 2,3-dimethoxypropyl dodecanoate. Molecular Formula: C17H34O4. Molecular Weight: 302.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it

Background
          Experimental colitis with features similar to inflammatory bowel disease (IBD) has initially been described. A detailed analysis of inflammatory cells has not yet been described. Therefore in this study we characterized the cells involved in the acute phase of the colitis and compared those findings to what is known about human IBD.
        
        
          Methods
          Colitis was induced in BALB/C and C57Bl6 mice by ingestion of 2.5% and 5% DSS in the drinking water for 8 days. Cells were labelled by immunohistochemical staining with F4/80 and ER-MP20 for macrophages, TIB 120 for MHC Class II presentation, and anti-CD4 and anti-CD8 antibodies. They were enumerated by using a novel method that employs video image analysis. Immunoglobulin-producing cells were enumerated by immunofluorescent staining for IgA, IgG and IgM and counting by using confocal microscopy.
        
        
          Results
          Inflammatory infiltrate in the acute phase of the dextran sulphate sodium (DSS) -induced colitis consists predominantly of macrophages, neutrophils and eosinophils. Neutrophils increase in numbers and crypt abscesses were also seen. Increased macrophage numbers were due to recently recruited monocytes from the peripheral circulation. It does not appear that there are any changes in T cell numbers or distribution. The inflammation induced changes in immunoglobulin-producing cells with IgA-producing cells affected the most.
        
        
          Conclusions
          The effect on Ig-producing cells depends on the percentage of DSS used to induce colitis. In general, 2.5% DSS induces an increase and 5% DSS a depletion of these cells.
Pharmacological and ischemic preconditioning of the human myocardium: mitoK

Background
          These studies investigate the role of mitoKATP channels, protein kinase C (PKC) and Mitogen activated protein kinase (p38MAPK) on the cardioprotection of ischemic (IP) and pharmacological preconditioning (PP) of the human myocardium and their sequence of activation.
        
        
          Results
          Right atrial appendages from patients undergoing elective cardiac surgery were equilibrated for 30 min and then subjected to 90 min of simulated ischemia followed by 120 min reoxygenation. At the end of each protocol creatinine kinase leakage (CK U/g wet wt) and the reduction of MTT to formazan dye (mM/g wet wt) were measured. Similar protection was obtained with α1 agonist phenylephrine, adenosine and IP and their combination did not afford additional cardioprotection. Blockade of mitoKATP channels with 5-hydroxydecanoate, PKC with chelerythrine, or p38MAPK with SB203580 abolished the protection of IP and of PP. In additional studies, the stimulation of mitoKATP channels with diazoxide or activation of PKC with PMA or p38MAPK with anisomycin induced identical protection to that of IP and PP. The protection induced by diazoxide was abolished by blockade of PKC and by blockade of p38MAPK. Furthermore, the protection induced by PMA was abolished by SB203580 but not by 5-hydroxydecanoate, whereas the protection induced by anisomycin was unaffected by either 5-hydroxydecanoate or chelerythrine.
        
        
          Conclusions
          Opening of mitoKATP channels and activation of PKC and p38MAPK are obligatory steps in the signal transduction cascade of IP and PP of the human myocardium with PKC activation being downstream of the opening of mitoKATP channels and upstream of p38MAPK activation.
P-ANCA vasculitic neuropathy with 12-year latency between onset of neuropathy and systemic symptoms

Background
          The differential diagnosis of chronic progressive multifocal asymmetric neuropathies is challenging. Vasculitic neuropathies, multifocal forms of chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathies, and asymmetric lower motor neuron disorders are important considerations.
        
        
          Case presentation
          We report a patient with an unusually long 12-year course of nonsystemic vasculitic neuropathy prior to the development of systemic manifestations.
        
        
          Conclusion
          We discuss some of the difficulties involved in the diagnosis of chronic progressive multifocal asymmetric neuropathies.
Compound 527374: 20,24-Dimethyl-hentriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 21,25-dimethyldotriacontanenitrile. Molecular Formula: C34H67N. Molecular Weight: 489.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Agreement of hip kinematics between two tracking marker configurations used with the 1 CODA pelvis during ergonomic roofing tasks

The anterior and posterior superior iliac spine markers are commonly used to define the pelvis, and these markers are predisposed to occlusion during three-dimensional motion capture. The occlusion of these markers leads to the use of various tracking marker configurations on the pelvis, which can create differences in kinematic results. The purpose of this investigation was to examine the agreement of CODA pelvis kinematic results when two different tracking marker configurations were used during ergonomic roofing tasks. Three-dimensional motion data was collected on seven male subjects while mimicking a standing and kneeling roofing task. Hip joint angles were computed using the CODA pelvis with two different tracking marker configurations, the Trochanter Tracking Method (TTM), and the Virtual Pelvis Tracking Method (VPTM).
Compound 528940: 4-(1,1,3,3-Tetramethylbutyl)phenyl-3-methyl-1-cyclobutenyl ether

Chemical compound data from PubChem database. IUPAC Name: 1-(4-methylcyclobuten-1-yl)oxy-4-(2,4,4-trimethylpentan-2-yl)benzene. Molecular Formula: C19H28O. Molecular Weight: 272.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Nebraska (NE)

This report presents Nebraska\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Nebraska for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
2013 CMHS Uniform Reporting System (URS) Table for South Dakota

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for South Dakota for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Chicago: Drug-Related Emergency Department Visits, 2004-2011 - All Misuse and Abuse

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving drug misuse or abuse in the Chicago metropolitan area, covering 2004-2011. Drug misuse/abuse visits include the use of illicit drugs, nonmedical use of pharmaceuticals, underage drinking and visits where alcohol was combined with another drug.
Patent AT-E400254-T1: [Translated] PHARMACEUTICAL NANOPARTICULAR PREPARATION OF A TACHICAN RECEPTOR ANTAGONIST

Chemical patent from PubChem database. Patent Number: AT-E400254-T1. Title: Pharmaceutical Formulation and Method of Use. Filing Date: 2013-01-26. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: The invention relates to pharmaceutical formulations containing active ingredients and methods for their therapeutic use in treating various medical c... IPC Classifications: B01J, C07C, C07D. This patent covers 45 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 528973: 1,2-Docosanediol, di-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl(1-trimethylsilyloxydocosan-2-yloxy)silane. Molecular Formula: C28H62O2Si2. Molecular Weight: 487.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399837-T1: [Translated] METHOD FOR PRODUCING CONJUGATE FATTY ACID ESTERS

Processes for preparing conjugated fatty acid products are described wherein (a) a composition which comprises a fatty acid ester having at least two unconjugated, carbon-carbon double bonds is provided; (b) the fatty acid ester is conjugated in the presence of a water-free base; (c) phosphoric acid is added to the conjugated fatty acid ester such that phosphate salts are precipitated; and (d) the precipitated phosphate salts are removed.
Plan Attributes PUF - PY2018

The Plan Attributes PUF (Plan-PUF) is one of the files that make up the Marketplace PUF. The Plan-PUF contains plan-level data on maximum out of pocket payments, deductibles, cost sharing, health savings account (HSA) eligibility, formulary ID, and other plan attributes. These data either originate from the Plans &amp; Benefits template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated). The issuer can also import data created in other templates (e.g., Network IDs from the Network ID template, Service Area IDs from the Service Area template, and Formulary IDs from the Prescription Drug template) to use as allowable values for the applicable fields in the Plans &amp; Benefits template, or enter these values manually.
Patent AT-E400230-T1: [Translated] DEVICE FOR REMOVAL OF FASTENERS FROM HUMAN TISSUE

A device for removal of fastening means from human tissue. The device comprises a shaft (2) having proximal and distal ends (3, 4) and a longitudinal centre line (C). The distal end (4) comprises a thread section (6) having a centre line (D) that is coaxial with the longitudinal centre line (C) of the shaft (2) and a left-hand thread (7) that screws itself around the centre line (D), and a counter surface (8a, 8b) that is disposed outside the thread (7) and has a surface component direction which intersects one of said centre lines (C, D). The counter surface (8a, 8b) is disposed so as to make contact with the fastening means to be removed when the thread (7) is rotated into a hole in the fastening means.
MD iMAP: Maryland Community Health Resource Commission - Dental Health Grantees

This is a MD iMAP hosted service. Find more information at  http://imap.maryland.gov. Dental Health Grantees - The Maryland Community Health Resources Commission works to expand access to health care services for low-income and under-served communities across the state.Feature Service Link:http://geodata.md.gov/imap/rest/services/Health/MD_CommunityHealthResourceCommission/FeatureServer/2 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively "the Data") is provided "as is" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Information Memorandum (IM-18-03)

This Information Memorandum (IM) informs title IV-E agencies of the Children’s Bureau’s intent to publish a NPRM to revise the AFCARS data points. This IM also informs title IV-E agencies of the final rule regarding implementation of the December 2016 AFCARS final rule and briefly summarizes public comments received in response to the Advanced Notice of Proposed Rulemaking (ANPRM), published in the Federal Register on March 15, 2018 (83 FR 11449
  
  

).

Metadata-only record linking to the original dataset. Open original dataset below.
CDC WONDER: Daily Air Temperatures and Heat Index

<p>The Daily Air Temperature and Heat Index data available on CDC WONDER are county-level daily average air temperatures and heat index measures spanning the years 1979-2010. Temperature data are available in Fahrenheit or Celsius scales. Reported measures are the average temperature, number of observations, and range for the daily maximum and minimum air temperatures, and also percent coverage for the daily maximum heat index. Data are available by place (combined 48 contiguous states, region, division, state, county), time (year, month, day) and specified maximum and minimum air temperature, and heat index value. The data are derived from the North America Land Data Assimilation System (NLDAS) through NLDAS Phase 2, a collaboration project among several groups: the National Oceanic and Atmospheric Administration (NOAA) National Centers for Environmental Prediction (NCEP) Environmental Modeling Center (EMC), the National Aeronautics and Space Administration (NASA) Goddard Space Flight Center (GSFC), Princeton University, the National Weather Service (NWS) Office of Hydrological Development (OHD), the University of Washington, and the NCEP Climate Prediction Center (CPC). In a study funded by the NASA Applied Sciences Program/Public Health Program, scientists at NASA Marshall Space Flight Center/ Universities Space Research Association developed the analysis to produce the data available on CDC WONDER.</p>
Macrofilaricides and onchocerciasis control, mathematical modelling of the prospects for elimination

Background
          In most endemic parts of the world, onchocerciasis (river blindness) control relies, or will soon rely, exclusively on mass treatment with the microfilaricide ivermectin. Worldwide eradication of the parasite by means of this drug is unlikely. Macrofilaricidal drugs are currently being developed for human use.
        
        
          Methods
          We used ONCHOSIM, a microsimulation mathematical model of the dynamics of onchocerciasis transmission, to explore the potentials of a hypothetical macrofilaricidal drug for the elimination of onchocerciasis under different epidemiological conditions, as characterized by previous intervention strategies, vectorial capacity and levels of coverage.
        
        
          Results
          With a high vector biting rate and poor coverage, a very effective macrofilaricide would appear to have a substantially higher potential for achieving elimination of the parasite than does ivermectin.
        
        
          Conclusions
          Macrofilaricides have a substantially higher potential for achieving onchocerciasis elimination than ivermectin, but high coverage levels are still key. When these drugs become available, onchocerciasis elimination strategies should be reconsidered. In view of the impact of control efforts preceding the introduction of macrofilaricides on the success of elimination, it is important to sustain current control efforts.
Patent AT-E399515-T1: [Translated] MODULAR SHOULDER JOINT POCKET

A glenoid implant assembly (10) is provided. The assembly includes a first component (12) for attachment to the glenoid fossa (14) of a scapula (16). The first component defines an assembly face (18) of the first component. The assembly also includes a second component (20) removably secured to the first component. The second component includes an assembly face (22) of the second component. The assembly face of the second component is in close approximation to the assembly face of the first component. The second component is attachable to the first component in a direction generally normal to the assembly faces.